Mason Lu

Title: Mason Lu: Innovator in Cancer Treatment

Introduction

Mason Lu is a prominent inventor based in Fremont, CA (US), known for his significant contributions to cancer treatment through innovative therapeutic agents. With a total of 4 patents, his work focuses on developing monoclonal antibodies that target specific cancer-related proteins.

Latest Patents

Mason Lu's latest patents include the development of Anti-TfR1 antibody MAb11-22.1 conjugates for cancer treatment. This invention provides a therapeutic agent aimed at treating, preventing, and diagnosing cancers associated with cells that overexpress transferrin receptor 1 (TfR1) and its variants. The agent is particularly effective against various cancers, including acute myeloid leukemia (AML), breast cancer, and glioblastoma. Another notable patent is the Anti-PODXL antibody MAI1738, which targets podocalyxin-like protein precursor isoform 2 (PODXL-v2). This therapeutic agent is designed for cancers that overexpress this protein, including gastric cancers and prostate cancer.

Career Highlights

Throughout his career, Mason Lu has worked with notable companies such as Medabome, Inc. and Seagate Technology Incorporated. His experience in these organizations has contributed to his expertise in developing innovative cancer therapies.

Collaborations

Mason has collaborated with talented individuals in the field, including Lynn Li and Steve Hwang. Their combined efforts have further advanced the research and development of effective cancer treatments.

Conclusion

Mason Lu's innovative work in cancer treatment through his patented inventions showcases his dedication to improving patient outcomes. His contributions to the field of oncology are significant and continue to inspire future advancements in medical research.